Bristol-Myers Squibb completes previously announced acquisition of IFM Therapeutics
Bristol-Myers Squibb Company announced that it has completed the previously announced planned acquisition of IFM therapeutics.
The transaction includes full rights to IFM’s preclinical STING (stimulator of interferon genes) and NLRP3 agonist programs focused on enhancing the innate immune response for treating cancer. IFM’s STING agonist program includes a lead asset that accelerates the company’s efforts against this target, while the NLRP3 agonist program includes a potential first-in-class pipeline candidate. A newly formed entity will be established by the current shareholders of IFM - IFM Therapeutics LLC – and it will retain IFM’s current personnel and facilities, as well as its remaining research programs, which include an NLRP3 antagonist program focused on curbing immune responses that lead to inflammatory diseases and fibrosis.
Most read news
Organizations
Other news from the department business & finance

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
Most read news
More news from our other portals
Last viewed contents
Tavistock_Clinic

Infection model from the 3D printer - Researchers print bacterial biofilms on human lung cells to study chronic lung infections
Polycystic_ovary_syndrome
BIOTECHNICA 2010 with new focus topics
Oncolytics Biotech Announces U.K. Phase II Clinical Trial Investigating REOLYSIN in Combination with Paclitaxel and Carboplatin
New coronavirus related to viruses from bats
Grover's_disease

New technology for enzyme design
Usher_syndrome
Sobell_House_Hospice

Destroying Tumor Cells with Calcium - Activating calcium channels leads to a deadly influx of calcium ions into tumor cells
